Adults with myelofibrosis whose disease no longer responded to or who could not tolerate Jakafi (ruxolitinib) or other…
Michela Luciano, PhD
Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg, where her research focused on the role of inflammation in acute myeloid leukemia. With a deep passion for scientific communication, Michela transitioned into her first role as a scientific writer in 2022. Outside of work, she enjoys street photography, mountain hiking, running, and spending as much time as possible outdoors.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Michela Luciano, PhD
Adults with myelofibrosis who received the experimental therapy navitoclax together with Jakafi (ruxolitinib) were about twice as likely…
Treatment with DISC-0974, Disc Medicine’s experimental antibody therapy for myelofibrosis-associated anemia, led to durable anemia responses across patient subgroups…
Treatment with Vonjo (pacritinib) before a stem cell transplant safely eased symptoms and spleen enlargement in people with myelofibrosis, while…